NCT07439757Recruiting
AI-Powered Precision Decision-Making for Pancreatic Diseases
A Multicenter Clinical Study on AI-Powered Precision Decision-Making Management for Pancreatic Diseases Using Contrast-Enhanced CT
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases. Using contrast-enhanced CT scans, the study compares the AI's recommendations against the decisions of experienced clinicians to verify the system's accuracy and safety in a real-world setting. Patients are categorized into three management groups: Intervention (surgery/treatment), Intensive Surveillance (close monitoring), or Routine Surveillance (standard follow-up). The primary goal is to determine if the AI system can reliably classify patients, reduce the risk of missing malignant lesions, and prevent unnecessary surgeries, thereby improving clinical decision-making for pancreatic conditions.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 23 Feb 2026
- Start date
- 1 Mar 2026
- Primary completion date
- 31 Oct 2029
- Lead sponsor
- Changhai Hospital
- Diseases
- Neuroendocrine tumours, Pancreatic cancer
- NCT number
- NCT07439757
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 1 Mar 2026 to the primary completion date, 31 Oct 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent participation in another interventional clinical trial.
Other illness
- History of pancreatic surgery.
- Contraindications to contrast-enhanced CT, including known hypersensitivity to iodinated contrast media or severe renal/hepatic dysfunction.
- Unsuitability for participation as determined by the investigator, including but not limited to: pregnancy or lactation, severe psychiatric disorders or cognitive impairment, significant comorbidities that may interfere with study results or patient safety.
Other
- Suboptimal image quality affecting diagnosis.
Who the study is looking for
- Clinically suspected pancreatic disease.
- Scheduled to undergo contrast-enhanced CT.
- Signed informed consent form indicating agreement to participate.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Changhai Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.